Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals

JAMA Internal Medicine

Volumn 175, Issue 1, 2015, Pages 88-99

  Okulicz, Jason F ^a,b   Le, Tuan D ^c,d   Agan, Brian K ^a,f   Camargo, Jose F ^c,d,e   Landrum, Michael L ^a,g,h   Wright, Edwina ^i,j,k   Dolan, Matthew J ^l   Ganesan, Anuradha ^a,m   Ferguson, Tomas M ^a,n   Smith, Davey M ^o,p   Richman, Douglas D ^o,p,q   Little, Susan J ^o   Clark, Robert A ^c,d   He, Weijing ^c,d   Ahuja, Sunil K ^c,d  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f Henry Jackson Foundation Advancement of Military Medicine Inc   (United States)

^g BROOKE ARMY MEDICAL CENTER   (United States)

^h Bellin Health   (United States)

ⁱ ALFRED HOSPITAL   (Australia)

^j BURNET INSTITUTE   (Australia)

^k MONASH UNIVERSITY   (Australia)

^l HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^m WALTER REED ARMY MEDICAL CENTER   (United States)

ⁿ TRIPLER ARMY MEDICAL CENTER   (United States)

^o UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^p VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HEPATITIS B VACCINE; HLA DR ANTIGEN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNE STATUS; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RISK REDUCTION; SEROCONVERSION; T LYMPHOCYTE ACTIVATION; TIME TO TREATMENT; VACCINATION; VIRUS IMMUNITY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFECTS; HIV INFECTIONS; IMMUNOLOGY; MULTICENTER STUDY; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; MALE; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920596760     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.4010     Document Type: Article

References (35)

1. Guihot A, Bourgarit A, Carcelain G, Autran B. Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol. 2011;32 (3):131-137.
2. Hirnschall G, Harries AD, Easterbrook PJ, Doherty MC, Ball A. The next generation of the World Health Organization's global antiretroviral guidance. J Int AIDS Soc. 2013;16:18757. doi:10. 7448 /IAS. 16. 1. 18757.
3. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Health Organizationwebsite. http://www. who. int/hiv /pub/guidelines/arv2013. Published June 2013. Accessed June 9, 2014.
4. DelvaW, Eaton JW, Meng F, et al. HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes. PLoS Med. 2012;9(7): e1001258. doi:10. 1371/journal. pmed. 1001258.
5. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382 (9903):1525-1533.
6. Katlama C, Deeks SG, Autran B, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet. 2013;381(9883):2109-2117.
7. Shytaj IL, Savarino A. A cure for AIDS: a matter of timing? Retrovirology. 2013;10:145. doi:10. 1186 /1742-4690-10-145.
8. Torti C, ProsperiM, Motta D, et al. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. Clin Microbiol Infect. 2012;18 (5):449-458.
9. Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009;48 (6):787-794.
10. Rodger AJ, Lodwick R, Schechter M, et al; INSIGHT SMART, ESPRIT Study Groups. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013; 27(6):973-979.
11. Le T,Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med. 2013;368(3):218-230.
12. Mocroft A, Furrer HJ, Miro JM, et al; Opportunistic InfectionsWorking Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD. The incidence of AIDS-defining illnesses at a current CD4 count-200 cells/?L in the post-combination antiretroviral therapy era. Clin Infect Dis. 2013;57(7):1038-1047.
13. Marin B, Thiebaut R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS. 2009;23(13):1743-1753.
14. Wilson EM, Sereti I. Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunol Rev. 2013;254(1):343-354.
15. Camargo JF, Kulkarni H, Agan BK, et al. Responsiveness of T cells to interleukin-7 is associated with higher CD4+ T cell counts in HIV-1-positive individuals with highly active antiretroviral therapy-induced viral load suppression. J Infect Dis. 2009;199(12):1872-1882.
16. Marconi VC, Grandits GA,Weintrob AC, et al; Infectious Disease Clinical Research Program HIV Working Group (IDCRP). Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the USMilitary HIV Natural History Study. AIDS Res Ther. 2010;7:14.
17. Marconi VC, Grandits G, Okulicz JF, et al; Infectious Disease Clinical Research Program (IDCRP) HIVWorking Group. Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS. PLoS One. 2011;6(5):e17956. doi:10. 1371/journal. pone. 0017956.
18. Krantz EM, Hullsiek KH, Okulicz JF, et al; Infectious Disease Clinical Research Program HIV Working Group. Elevated CD8 counts during HAART are associated with HIV virologic treatment failure. J Acquir Immune Defic Syndr. 2011;57(5): 396-403.
19. Kulkarni H, Okulicz JF, Grandits G, et al. Early postseroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-positive subjects receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2011;57(5):387-395.
20. Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med. 2011;171 (17):1560-1569.
21. Shepherd BE, Jenkins CA, Rebeiro PF, et al. Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy. Epidemiology. 2010;21(5):698-705.
22. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. http://www. cdc. gov/nchs/nhanes/nhanes -questionnaires. htm. Accessed January 13, 2014.
23. University of California, HIV Neurobehavioral Research Center (HNRC). https://hnrc. hivresearch . ucsd. edu/. Accessed August 6, 2014.
24. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
25. Landrum ML, Hullsiek KH, O'Connell RJ, et al; Infectious Disease Clinical Research Program HIV Working Group. Hepatitis B vaccine antibody response and the risk of clinical AIDS or death. PLoS One. 2012;7(3):e33488. doi:10. 1371/journal. pone . 0033488.
26. Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10(5): e1004078. doi:10. 1371/journal. ppat. 1004078.
27. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172. doi:10. 1136/bmj. a3172.
28. Jain V, HartogensisW, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis. 2013;208(8):1202-1211.
29. Hocqueloux L, Avettand-Fenoel V, Jacquot S, et al; AC32 (Coordinated Action on HIV Reservoirs) of the Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS). Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother. 2013;68(5):1169-1178.
30. Cohen MS, Chen YQ,McCauley M, et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365 (6):493-505.
31. ZengM, Southern PJ, Reilly CS, et al. Lymphoid tissue damage in HIV-1 infection depletes naive T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog. 2012;8(1): e1002437. doi:10. 1371/journal. ppat. 1002437.
32. Cagigi A, Rinaldi S, Cotugno N, et al. Early highly active antiretroviral therapy enhances B-cell longevity: a 5 year followup. Pediatr Infect Dis J. 2014;33(5):e126-e131. doi:10. 1097/INF . 0000000000000144.
33. Fidler S, Porter K, Ewings F, et al; SPARTAC Trial Investigators. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med. 2013;368(3): 207-217.
34. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al; HPTN 052-ACTG Study Team. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14(4):281-290.
35. ZengM, Haase AT, Schacker TW. Lymphoid tissue structure and HIV-1 infection: life or death for T cells. Trends Immunol. 2012;33(6):306-314.